Advertisement

ZNS-Pharmaka

  • W. Poser
  • Ulrike Ebert

Zusammenfassung

Psychopharmaka sind Arzneimittel, die zur Behandlung psychischer Erkrankungen geeignet sind. Es handelt sich um eine außerordentlich heterogene Gruppe von Arzneimitteln, die außer der Gruppenindikation praktisch nichts miteinander gemeinsam haben.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Uitti RJ, Ahlskog JE (1996) Comparative review of dopamine receptor agonists in Parkinson’s disease. CNS Drugs 5: 369 – 388CrossRefGoogle Scholar
  2. 2.
    Wachtel H (1991) Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transmission 3: 151 – 201CrossRefGoogle Scholar
  3. 3.
    Cedarbaum JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13: 141 – 178PubMedCrossRefGoogle Scholar
  4. 4.
    Kreiskott H, Kretzschmar R (1985) Neuere pharmakologische Aspekte zu den zentralen Anticholinergika Biperiden and Bornaprin. Symposium 7 – 9. März, Neurologische Universitätsklinik WienGoogle Scholar
  5. 5.
    Burke RE, Fahn S (1985) Serum trihexyphenidyl levels in the treatment of torsion dystonia. Neurology 35: 1066 – 1069PubMedCrossRefGoogle Scholar
  6. 6.
    Whiteman PD, Fowle ASE, Hamilton MJ et al. (1985) Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur J Clin Pharmacol 28: 73 – 78PubMedCrossRefGoogle Scholar
  7. 7.
    Prod Info Tremarit, 1996Google Scholar
  8. 8.
    Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14: 35 – 51PubMedCrossRefGoogle Scholar
  9. 9.
    Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7: 35 – 49PubMedCrossRefGoogle Scholar
  10. 10.
    Lang AE (1987) “Update on dopamine agonists in Parkinson’s disease: „beyond bromocriptine”. Can J Neurol Sci 14: 474 – 482PubMedGoogle Scholar
  11. 11.
    Lieberman AN, Goldstein M, Gopinathan G et al. (1987) D-1 and D-2 agonists in Parkinson’s disease. Can J Neurol Sci 14: 466 – 473PubMedGoogle Scholar
  12. 12.
    Langtry HD, Clissold SP (1990) Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson’s disease. Drugs 39: 491 – 506PubMedCrossRefGoogle Scholar
  13. 13.
    Marsden CD (1998) Clinical experience with cabergoline in patients with advanced Parkinson’s disease treated with levodopa. Drugs 1 (Suppl 1): 17 – 22CrossRefGoogle Scholar
  14. 14.
    Mönig H, Krack P (1998) Cabergolin. Dtsch Med Wschr 123: 1349 – 1350Google Scholar
  15. 15.
    Gerlach M, Yondim MBH, Riederer P (1996) Pharmacology of selegiline. Neurology 47: S137 – S145PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • W. Poser
  • Ulrike Ebert

There are no affiliations available

Personalised recommendations